Recon: Allergan Sues Pfizer; US Subpoenas AmerisourceBergen

• Bipartisan leaders of House panel press drug companies on opioid crisis (The Hill) (The Washington Post) (STAT-$)  (Bloomberg-$)
• Allergan Sues Pfizer Over Damages in Opioid Litigation (Bloomberg) (Reuters)
• U.S. subpoenas AmerisourceBergen over opioid products (Reuters)
• Clovis writes a $20 million check payable to the SEC, hoping to rid itself of the lingering roci probe (Endpoints) (Boston Business Journal-$) (Fierce)
• Thomas Hughes leaves Zafgen to take CEO role at Navitor (Fierce) (Endpoints)
• Google Glass paired with the right software could make a big difference for kids with autism (Mashable) (Reuters)

• To Get the Latest Drugs, Head to China (Bloomberg)
• China isn’t yet ready to conduct clinical trials for the pharma industry (STAT)
• Spain's Almirall bets on dermatology with $650 million U.S. deal (Reuters) (Fierce)
• EMA grants PRIME status for Roche Huntington's drug (PharmaTimes) (Endpoints)
• Early access to medicines scheme (EAMS) scientific opinion: patisiran-LNP to treat adults with hereditary transthyretin-mediated amyloidosis (MHRA) (Press)
• Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital (Endpoints) (The Pharma Letter)
• Ebola outbreak in DRC sets up another test for experimental treatments (STAT)
• WHO to know soon if new Congo Ebola outbreak can use vaccine (AP News) (Reuters)
• New Ebola outbreak kills 20 in DR Congo just nine days after health workers declared virus contained (The Guardian) (Reuters)
• WHO warns of new Yemen cholera surge, asks for ceasefire to vaccinate (Reuters)
• Ireland woos Kerala-based companies, positions itself as base to access European markets (The Hindu Business Line)

• Cellectis snaps up Novartis VP (The Pharma Letter-$) (Endpoints) (Fierce)
• How drug companies are beating Trump at his own game (Politico)
• The difficult search for the right recipe in cancer immunotherapy (GEN)
• Drugs could account for more health spending than we thought (Axios)
• FTC, FDA Team Up to Fight Drug Monopolies, High Prices (Bloomberg-$)
• Intercept Shares Rise as Drug Sales Recover After Patient Deaths (Bloomberg-$)
• Under pressure from investors, Cardinal Health agrees to bolster opioid distribution oversight (STAT-$)
• To pay for cutting-edge CAR-T therapies, Medicare plays it safe, for now (STAT-$)
• Poison control calls spike for unapproved drug that produces opioid-like highs (STAT)
• Antianxiety drugs — often more deadly than opioids — are fueling the next drug crisis in US (CNBC)
• Cashing in on DNA: race on to unlock value in genetic data (Reuters)
• Exploring validation and data integrity in pharma (PharmaTimes)
• Latest PRV sale further evidence of sliding value (BioPharma Dive)
• F.D.A. Did Not Intervene to Curb Risky Fentanyl Prescriptions (NYT)
• Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone (Scrip-$)
• Listen: Inexpensive Nerve Drug Often Abused As Opioid Epidemic Grows (KHN)
• 6 Reasons Celgene Remains The Best Valued Large-Cap Pharma Stock (Seeking Alpha)
• Regeneron plots DTC advertising and discount push to put Eylea back on track (Fierce)

• Bristol-Myers, Scripps research team touts a new way to control 3D architecture of genetic drugs (Endpoints)
• Apomorphine results show reduced tremors in Parkinsons patients (The Pharma Letter)
• Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA (Scrip-$)
• Epizyme shuts down failing lymphoma trial as FDA imposes clinical hold (Pharmafile)
• Zithromax, Zmax (azithromycin): FDA Warning - Increased Risk of Cancer Relapse With Long-Term Use After Donor Stem Cell Transplant (FDA)
• CMS Grants New Technology Add-on Payment to ZEMDRI (plazomicin) (Press)

• Wearable devices: Useful medical insights or just more data? (ScienceDaily)
• Hologic’s stock dips despite strong quarterly earnings (Fierce)
• Endomag nets approval for liquid, magnetic, breast-mapping tracer (Fierce)
• Stryker touts 3D-printed Tritanium cage study results (MassDevice)
• FDA Issues Final Guidance on Use of EHR Data in Clinical Investigations (AAMI)
• Recreational Genetics or Research Enterprise? Cloudy Consent Issues Arising from Direct-to-Consumer Genetic Testing (Bill of Health)
• Boston Scientific Closes Acquisition of Claret Medical, Inc., Announces Positive Reimbursement Decision (Press)
• Hologic Announces FDA Clearance of the Panther Fusion GBS Assay (Press)
• Data from the ASSURE Study of Long-Term Use of RELiZORB Published in Journal of Pediatric Gastroenterology and Nutrition (Press)

• Watson Health is committed to using AI to tackle major healthcare challenges (IBM Watson Health)
• Influenza Virus Vaccine for the 2018-2019 Season (FDA)
• Webinar - FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder - July 25, 2018 (FDA)
• FDA Grand Rounds: How Simulation Can Transform Regulatory Pathways (FDA)
• 2018 Meeting Materials, Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee) (FDA)
• What They Said – FDA Press Releases 2d Quarter 2018 (Eye on FDA)
• FCC Kicks Off Conversation On $100M Telehealth Program (Law360-$) (FCC)
• Department of Justice Announces Expansion of Program to Enhance Tribal Access to National Crime Information Databases (DOJ)
• FDA guidance encourages EHR use but doesn’t solve interoperability challenges: Industry responds (Outsourcing-Pharma)
• CMS drops new EHR incentive requirements (Politico)
• Stem Cell Clinics Face Long Odds Against FDA in Legal Fight (Bloomberg-$)
• Welcome to the New Health-Care Debate (Bloomberg)
• JUUL Labs responds to FDA concerns about flavored e-liquids (TechCrunch)
• Can eConsults Lower Patient Wait Times And Medicaid Spending Problems? (Forbes)
• Apple becomes first $1 trillion company in history (Chicago Tribune)

• FDA Advisory Committee Calendar

• AZ and MSD get orphan designation for neurofibromatosis drug (PharmaTimes)
• Patents – recent trends in the pharma sector (EPM Magazine)
• Smoking linked to increased atrial fibrillation risk (Reuters)
• EMA’s interaction with industry stakeholders: Annual report 2017 (EMA)
• Vismodegib hard capsule 150 mg product-specific bioequivalence guidance (EMA)
• Updated: Statutory guidance on MHRA fees (MHRA)

• This Biotech Just Had a $903 Million IPO—And It's Disappointed (Fortune)
• Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut (South China Morning Post)

• In a push to pharma exports, states get NOC booster shot (Times of India)
• GSK employees demand reopening of factory (The Daily Star)
• Govt amends MD Rules to remove regulatory hurdle, all NABL-accredited labs can issue performance report on IVDs (Pharmabiz)
• Two medical device cos soon to start operations at India’s first govt funded medical device park in Andhra Pradesh (Pharmabiz)

• Mosquito Wars - A Big Win In Australia Brings Hopeful News For Southern U.S. (Forbes)
• Chronic care patients forced to have My Health Records to access government's Health Care Homes program (Healthcare IT News)

• EpiPen shortage is critical – and not easy to fix (The Globe and Mail)

• What Causes Morning Sickness? (NYT)
• Most U.S. kids not getting developmental screening (Reuters)
• Please Do Not Wash Or Reuse Your Condoms, The CDC Warns (BuzzFeed)
• Does Moderate Alcohol Really Protect Against Dementia? It's Unclear (And There Are Other Risks) (Forbes)